Eledon Pharmaceuticals, Inc. (ELDN)
US — Healthcare Sector
Automate Your Wheel Strategy on ELDN
With Tiblio's Option Bot, you can configure your own wheel strategy including ELDN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ELDN
- Rev/Share 0.0025
- Book/Share 1.4856
- PB 1.8713
- Debt/Equity 0.0077
- CurrentRatio 13.9051
- ROIC -0.4965
- MktCap 166471404.0
- FreeCF/Share -0.7078
- PFCF -3.0495
- PE -11.2564
- Debt/Assets 0.0055
- DivYield 0
- ROE -0.2537
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ELDN | H.C. Wainwright | -- | Buy | -- | $9 | June 18, 2025 |
| Initiation | ELDN | Guggenheim | -- | Buy | -- | $9 | Jan. 28, 2025 |
News
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
ELDN
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Eledon Pharmaceuticals, Inc. (ELDN)
- IPO Date 2014-09-17
- Website https://eledon.com
- Industry Biotechnology
- CEO Dr. David-Alexandre C. Gros M.D., Ph.D.
- Employees 31
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.